|
Delayed
Bombay S.E.
06:19:16 03/11/26 pm AEDT
|
5-day change | 1st Jan Change | ||
| 4,616.25 INR | +0.68% |
|
+0.23% | +20.16% |
| Market Cap | 1,744B 18.42B 16.45B 15.09B 13.73B 25.74B 26.25B 180B 72.67B 921B 69.14B 67.67B 2,907B | P/E 2027 * |
70.5x | P/E 2028 * | 51x |
|---|---|---|---|---|---|
| Enterprise Value | 1,867B 19.73B 17.61B 16.16B 14.7B 27.56B 28.11B 193B 77.81B 986B 74.03B 72.46B 3,113B | EV / Sales 2027 * |
9.35x | EV / Sales 2028 * | 8.19x |
| Free-Float |
41.38% | Yield 2027 * |
0.65% | Yield 2028 * | 0.76% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| TORNTPHARM | Delayed | |
NSE India S.E.
| TORNTPHARM | Delayed |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | +0.68% | ||
| 1 week | +0.23% | ||
| Current month | -0.41% | ||
| 1 month | -2.92% | ||
| 3 months | -8.02% | ||
| 6 months | +8.57% | ||
| Current year | +20.16% |
| 1 week | 4,489.75 |  | 4,668.55 |
| 1 month | 4,465.35 | | 4,793.55 |
| Current year | 3,724.1 | | 5,249.95 |
| 1 year | 3,532.85 | | 5,249.95 |
| 3 years | 1,924.85 | | 5,249.95 |
| 5 years | 1,242.5 | | 5,249.95 |
| 10 years | 571.75 | | 5,249.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 01/08/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 01/09/2018 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 30/07/2014 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 07/03/2019 |
| Director/Board Member | 59 | 29/07/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/11/24 | Buy | Chief Operating Officer | 930,144 | 0.2748% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.68% | +0.23% | +27.23% | +135.53% | 18.42B | |
| -0.46% | +10.31% | +63.52% | +143.15% | 1,257B | |
| -0.97% | +1.60% | +43.25% | +80.09% | 651B | |
| -2.05% | +0.73% | +32.47% | +101.62% | 510B | |
| -1.54% | +0.18% | +53.42% | +66.79% | 388B | |
| -0.78% | +5.51% | +72.55% | +44.25% | 366B | |
| -1.69% | +3.17% | +32.49% | +55.35% | 303B | |
| -0.72% | +7.83% | +11.15% | +33.76% | 288B | |
| -0.12% | +4.68% | +55.97% | +74.59% | 252B | |
| -0.21% | +7.34% | +42.19% | +109.69% | 211B | |
| Average | -0.72% | +4.17% | +43.42% | +84.48% | 424.51B | |
| Weighted average by Cap. | -0.73% | +5.28% | +49.09% | +93.52% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 200B 2.11B 1.88B 1.73B 1.57B 2.95B 3.01B 20.64B 8.32B 105B 7.92B 7.75B 333B | 224B 2.37B 2.12B 1.94B 1.77B 3.31B 3.38B 23.19B 9.35B 118B 8.9B 8.71B 374B |
| Net income | 23.96B 253M 226M 207M 189M 354M 361M 2.48B 998M 12.65B 950M 930M 39.95B | 33.89B 358M 320M 293M 267M 500M 510M 3.5B 1.41B 17.89B 1.34B 1.32B 56.51B |
| Net Debt | 123B 1.3B 1.16B 1.07B 972M 1.82B 1.86B 12.76B 5.14B 65.15B 4.89B 4.79B 206B | 92.93B 982M 876M 804M 732M 1.37B 1.4B 9.61B 3.87B 49.05B 3.68B 3.61B 155B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/11/26 | INR 4,616.25 | +0.68% | 1,749 |
| 02/11/26 | INR 4,585.10 | -1.08% | 85,713 |
| 30/10/26 | INR 4,635.15 | +1.56% | 62,448 |
| 29/10/26 | INR 4,564.10 | +0.08% | 34,455 |
| 28/10/26 | INR 4,560.35 | -0.98% | 4,303 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
